Abstract:Previous studies have demonstrated that 3-n-butylphthalide(NBP) can inhibit platelet aggregation and thrombosis.Moreover,isosorbide nitrate is characterized as a classic NO-donor drug,which presents certain antiplatelet activity.In our work,the ring-opening derivative of NBP and the panel of isosorbide mononitrate were combined together,expecting this hybrid molecule can exhibit synergic action on inhibitory of antiplatelet aggregation activity via releasing NBP and other potent compounds as well as NO.All twelve target compounds are new derivatives,among which 4a and 5a were synthesized by seccessive hydrolysis and esterification and the other ten compounds were sythesized by further ammonification.Their structures were confirmed by MS and 1H-NMR.The effects of individual compounds on ADP-induced in vitro platelet aggregation were preliminarily evaluated by Born′s turbidimetric method.In comparison with NBP,4e and 5e displayed more potent inhibitory activity on platelet aggregation in vitro.The levels of NO produced by target compounds were determined by Griess assay.Compared with other compounds,4e and 5e also released moderate levels of NO,supporting that the levels of NO produced by these NO-NBP were positively correlated with the potencies on inhibiting platelet aggregation in vitro.In conclution,4e and 5e could be further developed as antiplatelet agents for the prevention of ischemic stroke.

Synthesis and Biological Evaluation of Nitric Oxide (No)-Hydrogen Sulfide (h2s) Releasing Derivatives of (S)-3-n-butylphthalide As Potential Antiplatelet Agents

Design, Synthesis and Evaluation of Nitric Oxide Releasing Derivatives of 3-N-butylphthalide As Antiplatelet and Antithrombotic Agents.

Design, Synthesis And Biological Evaluation Of Hydrogen Sulfide Releasing Derivatives Of 3-N-Butylphthalide As Potential Antiplatelet And Antithrombotic Agents

Synthesis and evaluation of nitric oxide-releasing derivatives of 3-n-butylphthalide as anti-platelet agents.

Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents.

Synthesis and anti-platelet activities of nitric oxide-releasing derivatives of 3-butylphthalide

Discovery of a Ring-Opened Derivative of 3-N-butylphthalide Bearing NO/H2S-donating Moieties As a Potential Anti-Ischemic Stroke Agent.

Synthesis and Biological Evaluation of N-Butylphthalide Derivatives As Anti-Platelet Aggregation Agents

Synthesis of Novel 3-Butylphthalide Derivatives Containing Isopentenylphenol Moiety as Potential Antiplatelet Agents for the Treatment of Ischemic Stroke

Synthesis and in Vitro Antiplatelet Aggregation Activity of Isosorbide Mononitrate-Based 3-N-butylphthalide Derivatives

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Novel Hybrids of Optically Active Ring-Opened 3-N-butylphthalide Derivative and Isosorbide As Potential Anti-Ischemic Stroke Agents.

Synthesis and biological evaluation of N 6 derivatives of 8-azapurine as novel antiplatelet agents

Design and Synthesis of the Ring-Opened Derivative of 3-N-butylphthalide-ferulic Acid-Glucose Trihybrids As Potential Anti-Ischemic Agents

Design, Synthesis and Evaluation of Novel 2-Amino-3-(naphth-2-yl)propanoic Acid Derivatives As Potent Inhibitors of Platelet Aggregation

Synthesis and Biological Evaluation of N6 Derivatives of 8-Azapurine As Novel Antiplatelet Agents

Dl-3-N-Butylphthalide Inhibits Platelet Activation Via Inhibition Of Cpla2-Mediated Txa(2) Synthesis And Phosphodiesterase

Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.

Synthesis and Biological Evaluations of Novel Nitric Oxide-donating Derivatives of [1,2,4]triazol-5(4H)-one with N-phenylpyrrolyl-2-tetrazole Moiety as Anti-hypertension Candidates

Design, Synthesis and Biological Evaluation of Hydrogen Sulfide-Releasing Isochroman-4-one Derivatives As New Antihypertensive Agent Candidates.

Design, Synthesis and Evaluation of 1,4-Benzodioxine Derivatives As Novel Platelet Aggregation Inhibitors.